Update Series (2021) Lesson 3: Ambulatory Evaluation of the Infertile Male
Now in its 40th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed in consultation with and edited by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.
At the conclusion of this continuing medical education activity, the participant will be able to describe the necessary examination and laboratory evaluation for the initial evaluation of a subfertile male.
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence-Based Content: It is the policy of the AUA to ensure that the content contained in this CME enduring material activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor and/or AUA COI Review Work Group.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Individual authors’ disclosures are located with their articles in each issue of The Update Series.
Update Series Advisory Group
|Benjamin Newell Breyer, MD, FACS||Nothing to disclose|
|Michael S. Cookson, MD, MMHC||TesoRx Pharma LLC||Consultant or Advisor|
|Astellas Pharma, Inc.||Consultant or Advisor|
|Merck||Consultant or Advisor|
|Bayer Healthcare Pharmaceuticals||Consultant or Advisor|
|Ferring Pharmaceuticals||Consultant or Advisor|
|Myovant Sciences||Consultant or Advisor|
|E. Ann Gormley, MD||American Board of Medical Subspecialties||Leadership Position|
|Cheryl Taylore Lee, MD||Merck||Consultant or Advisor|
|Brian R. Matlaga, MD, MPH||Boston Scientific||Consultant or Advisor|
|John Patrick Mulhall, MD||The Journal of Sexual Medicine||Leadership Position|
|Vault||Consultant or Advisor|
|Curtis Nickel, MD, FRCSC||National Institutes of Health||Scientific Study or Trial|
|Canadian Institute of Health Research||Scientific Study or Trial|
|RedLeaf Medical||Scientific Study or Trial|
|MicroGenDx||Scientific Study or Trial|
|Inmunotek||Scientific Study or Trial|
|Valensa||Scientific Study or Trial|
|TEVA||Consultant or Advisor|
|Farr Laboratories||Consultant or Advisor|
|Alivio Therapeutics||Consultant or Advisor|
|Seikagaku Corporation||Consultant or Advisor|
|JT Pharma||Consultant or Advisor|
|Craig Stuart Niederberger, MD||American Society for Reproductive Medicine||Leadership Position|
|Ferring Pharmaceuticals||Scientific Study or Trial|
|J. Kellogg Parsons, MD, MHS||Dendron||Consultant or Advisor|
|Boston Scientific||Consultant or Advisor|
|Stacy T. Tanaka, MD, MS, FAAP, FACS||Centers for Disease Control and Prevention (CDC)||Scientific Study or Trial|
|Journal of Urology||Health Publishing|
|J. Christian Winters, MD||StimGuard||Consultant or Advisor|
|Christopher S. Saigal, MD||WiseCare||Consultant or Advisor|
|Ceeva||Consultant or Advisor|
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA activity is prohibited without the written permission from individual authors and the American Urological Association.
Release date: January 2021
Expiration date: January 2024
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation